← All trials
NCT03653832
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2018
- Primary completion
- Feb 28, 2021
- Completion date
- Jul 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 1737
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of EdinburghLead sponsor
- Cardiff UniversityCollaborator
- University of QueenslandCollaborator
- University of LondonCollaborator
- Queen's University, BelfastCollaborator
- University of ManchesterCollaborator
- University of WarwickCollaborator
- University of EdinburghOverall official - principal investigator
- Edinburgh Napier UniversityCollaborator
- West Hertfordshire Hospitals NHS TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.